Orthopedic device company Enovis recorded $565 million in net sales during the second quarter, according to an Aug. 7 news release from the company.
Here are five more financial notes to know:
- The company’s 2025 second quarter sales grew 7% on a reported basis and 5% on an organic basis compared to the second quarter in 2024.
- Enovis reported a second-quarter net loss of $37 million and adjusted EBITDA of $97 million.
- The company expects 2025 revenue to be between $2.22 and $2.25 billion, up slightly from previous projections.
- Through the first two quarters of 2025, Enovis has $1.12 billion in net sales, up from $1.04 billion in net sales through the first half of 2024.
- Enovis had a gross profit margin of 59.3% in the second quarter of 2025, compared to 55% in the second quarter of 2024.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
